Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1406-1408

  Muthu Raja, Karthick Raja ^a   Kovarova, Lucie ^a   Hajek, Roman ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DEXAMETHASONE; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; TRANSCRIPTION FACTOR FOXP3;

ADULT; CANCER STAGING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOCYTE COUNT; MIDDLE AGED; MULTIPLE MYELOMA; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84862742268     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.652106     Document Type: Letter

References (13)

1. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009;23:449-456.
2. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22-32.
3. Tohnya TM, Figg WD. Immunomodulation of multiple myeloma. Cancer Biol Th er 2004;3:1060-1061. (Pubitemid 41350985)
4. Davies FE, Raje N, Hideshima T, et al. Th alidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
5. Minnema MC, van der Veer MS, Aarts T, et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4 + Foxp3 + T cells. Leukemia 2009;23:605-607.
6. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF down-modulates the function of human CD4 + CD25hi T-regulatory cells. Blood 2006;108:253-261. (Pubitemid 43990636)
7. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-167.
8. Doganci A, Eigenbrod T, Krug N, et al. Th e IL-6R alpha chain controls lung CD4 + CD25 + Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005;115:313-325. (Pubitemid 40385473)
9. Doganci A, Sauer K, Karwot R, et al. Pathological role of IL-6 in the experimental allergic bronchial asthma in mice. Clin Rev Allergy Immunol 2005;28:257-270.
10. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-1790. (Pubitemid 38268973)
11. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(Suppl. 1):I107-I113.
12. Gupta R, Ganeshan P, Hakim M, et al. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leuk Res 2011;35:874-878.
13. Gri G, Piconese S, Frossi B, et al. CD4 + CD25 + regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008;29:771-781.